메뉴 건너뛰기




Volumn 121, Issue 3, 2010, Pages 154-160

Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis

Author keywords

Adverse effects; Multiple sclerosis; Treatment

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE;

EID: 76249099041     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01285.x     Document Type: Article
Times cited : (24)

References (35)
  • 1
    • 0142017677 scopus 로고    scopus 로고
    • World Health Organization, WHO. Geneva, Switzerland. World Health Organization
    • World Health Organization, WHO. Adherence to long-term therapy: evidence for action. Geneva, Switzerland: World Health Organization, 2003.
    • (2003) Adherence to Long-term Therapy: Evidence for Action.
  • 2
    • 20044388168 scopus 로고    scopus 로고
    • Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone)
    • Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005 12: 425 431.
    • (2005) Eur J Neurol , vol.12 , pp. 425-431
    • Haas, J.1    Firzlaff, M.2
  • 3
    • 0035018884 scopus 로고    scopus 로고
    • Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject
    • Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001 23: 125 132.
    • (2001) Ann Behav Med , vol.23 , pp. 125-132
    • Mohr, D.C.1    Boudewyn, A.C.2    Likosky, W.3    Levine, E.4    Goodkin, D.E.5
  • 4
    • 0030332317 scopus 로고    scopus 로고
    • Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment
    • Mohr DC, Goodkin DE, Likosky W et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996 2: 222 226.
    • (1996) Mult Scler , vol.2 , pp. 222-226
    • Mohr, D.C.1    Goodkin, D.E.2    Likosky, W.3
  • 5
    • 0032438047 scopus 로고    scopus 로고
    • Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a
    • Mohr DC, Likosky W, Boudewyn AC et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998 4: 487 489.
    • (1998) Mult Scler , vol.4 , pp. 487-489
    • Mohr, D.C.1    Likosky, W.2    Boudewyn, A.C.3
  • 6
    • 20144382021 scopus 로고    scopus 로고
    • Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis
    • Rio J, Porcel J, Tellez N et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005 11: 306 309.
    • (2005) Mult Scler , vol.11 , pp. 306-309
    • Rio, J.1    Porcel, J.2    Tellez, N.3
  • 7
    • 0042932742 scopus 로고    scopus 로고
    • Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS
    • Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003 61: 551 554.
    • (2003) Neurology , vol.61 , pp. 551-554
    • Tremlett, H.L.1    Oger, J.2
  • 9
    • 0037803726 scopus 로고    scopus 로고
    • Interferon beta in multiple sclerosis: Experience in a British specialist multiple sclerosis centre
    • Dubois BD, Keenan E, Porter BE et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003 74: 946 949.
    • (2003) J Neurol Neurosurg Psychiatry , vol.74 , pp. 946-949
    • Dubois, B.D.1    Keenan, E.2    Porter, B.E.3
  • 10
    • 13844315516 scopus 로고    scopus 로고
    • Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns
    • O'rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005 11: 46 50.
    • (2005) Mult Scler , vol.11 , pp. 46-50
    • O'Rourke, K.E.1    Hutchinson, M.2
  • 11
    • 39749102351 scopus 로고    scopus 로고
    • Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis
    • Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008 59: 131 135.
    • (2008) Eur Neurol , vol.59 , pp. 131-135
    • Portaccio, E.1    Zipoli, V.2    Siracusa, G.3    Sorbi, S.4    Amato, M.P.5
  • 12
    • 22144447781 scopus 로고    scopus 로고
    • Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre
    • Rio J, Tintore M, Nos C, Tellez N, Galan I, Montalban X. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 2005 252: 795 800.
    • (2005) J Neurol , vol.252 , pp. 795-800
    • Rio, J.1    Tintore, M.2    Nos, C.3    Tellez, N.4    Galan, I.5    Montalban, X.6
  • 13
    • 0347599145 scopus 로고    scopus 로고
    • Long-term interferon-beta treatment for multiple sclerosis
    • Ruggieri RM, Settipani N, Viviano L et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003 24: 361 364.
    • (2003) Neurol Sci , vol.24 , pp. 361-364
    • Ruggieri, R.M.1    Settipani, N.2    Viviano, L.3
  • 14
    • 46349110053 scopus 로고    scopus 로고
    • Adherence to the immunomodulatory drugs for multiple sclerosis: Contrasting factors affect stopping drug and missing doses
    • Tremlett H, Van Der Mei I, Pittas F et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Safety 2008 17: 565 576.
    • (2008) Pharmacoepidemiol Drug Safety , vol.17 , pp. 565-576
    • Tremlett, H.1    Van Der Mei, I.2    Pittas, F.3
  • 16
    • 0033754825 scopus 로고    scopus 로고
    • Interferon-beta treatment for patients with multiple sclerosis: The patients' perceptions of the side-effects
    • Gottberg K, Gardulf A, Fredrikson S. Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects. Mult Scler 2000 6: 349 354.
    • (2000) Mult Scler , vol.6 , pp. 349-354
    • Gottberg, K.1    Gardulf, A.2    Fredrikson, S.3
  • 18
    • 0020686503 scopus 로고
    • New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
    • Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 13: 227 231.
    • (1983) Ann Neurol , vol.13 , pp. 227-231
    • Poser, C.M.1    Paty, D.W.2    Scheinberg, L.3
  • 19
    • 0034955141 scopus 로고    scopus 로고
    • Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis
    • Mcdonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 50: 121 127.
    • (2001) Ann Neurol , vol.50 , pp. 121-127
    • McDonald, W.I.1    Compston, A.2    Edan, G.3
  • 20
    • 0021035886 scopus 로고
    • Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
    • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33: 1444 1452.
    • (1983) Neurology , vol.33 , pp. 1444-1452
    • Kurtzke, J.F.1
  • 21
    • 0034727059 scopus 로고    scopus 로고
    • Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
    • Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 343: 898 904.
    • (2000) N Engl J Med , vol.343 , pp. 898-904
    • Jacobs, L.D.1    Beck, R.W.2    Simon, J.H.3
  • 22
    • 34547497820 scopus 로고    scopus 로고
    • Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study
    • Kappos L, Freedman MS, Polman CH et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 370: 389 397.
    • (2007) Lancet , vol.370 , pp. 389-397
    • Kappos, L.1    Freedman, M.S.2    Polman, C.H.3
  • 23
    • 33645100122 scopus 로고    scopus 로고
    • IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event
    • Kinkel RP, Kollman C, O'connor P et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006 66: 678 684.
    • (2006) Neurology , vol.66 , pp. 678-684
    • Kinkel, R.P.1    Kollman, C.2    O'Connor, P.3
  • 24
    • 33244466021 scopus 로고    scopus 로고
    • Natural history of multiple sclerosis: A unifying concept
    • DOI 10.1093/brain/awl007
    • Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006 129: 606 616. (Pubitemid 43278223)
    • (2006) Brain , vol.129 , Issue.3 , pp. 606-616
    • Confavreux, C.1    Vukusic, S.2
  • 25
    • 0038149171 scopus 로고    scopus 로고
    • Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis
    • Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs 2003 35: 163 170.
    • (2003) J Neurosci Nurs , vol.35 , pp. 163-170
    • Fraser, C.1    Hadjimichael, O.2    Vollmer, T.3
  • 26
    • 54349110518 scopus 로고    scopus 로고
    • Use of health care services and satisfaction with care in people with multiple sclerosis in Stockholm County: A population-based study
    • Gottberg K, Einarsson U, Ytterberg C, Fredrikson S, Von Koch L, Holmqvist LW. Use of health care services and satisfaction with care in people with multiple sclerosis in Stockholm County: a population-based study. Mult Scler 2008 14: 962 971.
    • (2008) Mult Scler , vol.14 , pp. 962-971
    • Gottberg, K.1    Einarsson, U.2    Ytterberg, C.3    Fredrikson, S.4    Von Koch, L.5    Holmqvist, L.W.6
  • 27
    • 33746445987 scopus 로고    scopus 로고
    • Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis
    • Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006 38: 167 171.
    • (2006) J Neurosci Nurs , vol.38 , pp. 167-171
    • Cox, D.1    Stone, J.2
  • 28
    • 1842432687 scopus 로고    scopus 로고
    • Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: A nursing approach
    • Denis L, Namey M, Costello K et al. Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach. J Neurosci Nurs 2004 36: 10 22.
    • (2004) J Neurosci Nurs , vol.36 , pp. 10-22
    • Denis, L.1    Namey, M.2    Costello, K.3
  • 29
    • 0035525120 scopus 로고    scopus 로고
    • Adherence to disease-modifying therapy in multiple sclerosis. Part II
    • Holland N, Wiesel P, Cavallo P et al. Adherence to disease-modifying therapy in multiple sclerosis. Part II. Rehabil Nurs 2001 26: 221 226.
    • (2001) Rehabil Nurs , vol.26 , pp. 221-226
    • Holland, N.1    Wiesel, P.2    Cavallo, P.3
  • 30
    • 0035468790 scopus 로고    scopus 로고
    • Adherence to disease-modifying therapy in multiple sclerosis: Part i
    • Holland N, Wiesel P, Cavallo P et al. Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehabil Nurs 2001 26: 172 176.
    • (2001) Rehabil Nurs , vol.26 , pp. 172-176
    • Holland, N.1    Wiesel, P.2    Cavallo, P.3
  • 31
    • 10344225070 scopus 로고    scopus 로고
    • Strategies for managing the side effects of treatments for multiple sclerosis
    • Langer-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology 2004 63: S35 41.
    • (2004) Neurology , vol.63 , pp. 35-41
    • Langer-Gould, A.1    Moses, H.H.2    Murray, T.J.3
  • 32
    • 25144458103 scopus 로고    scopus 로고
    • Innovative ways of responding to the information needs of people with MS
    • Maclean R, Russell A. Innovative ways of responding to the information needs of people with MS. Br J Nurs 2005 14: 754 757.
    • (2005) Br J Nurs , vol.14 , pp. 754-757
    • MacLean, R.1    Russell, A.2
  • 33
    • 0032997515 scopus 로고    scopus 로고
    • Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis
    • Mohr DC, Goodkin DE, Masuoka L et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler 1999 5: 192 197.
    • (1999) Mult Scler , vol.5 , pp. 192-197
    • Mohr, D.C.1    Goodkin, D.E.2    Masuoka, L.3
  • 35
    • 27744509228 scopus 로고    scopus 로고
    • Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: Report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis
    • Sorensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005 12: 817 827.
    • (2005) Eur J Neurol , vol.12 , pp. 817-827
    • Sorensen, P.S.1    Deisenhammer, F.2    Duda, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.